NCT03288740View on ClinicalTrials.gov

A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 21, 2017

Primary Completion Date

July 10, 2018

Study Completion Date

August 7, 2018

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

Semaglutide 0.5 mg

A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.

DRUG

Placebo (semaglutide 0.5 mg)

A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.

DRUG

Semaglutide 1.0 mg

A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.

DRUG

Placebo (semaglutide 1.0 mg)

A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.

Trial Locations (1)

100730

Novo Nordisk Investigational Site, Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY